We are a company limited by shares organized under the laws of Israel. We were incorporated in Israel in 2003 as a privately held company. In February 2007, we completed an initial public offering of our ordinary shares on the Tel Aviv Stock Exchange (TASE), and we voluntarily delisted from the TASE in January 2018.
Partnerships Max Planck Society / UMG (exclusive license and research collaboration agreements)
Indications
COVID-19 (treatment and prophylactic prevention)(Preclinical)
Status note NanoAbs covering all known variants of concern under selection; preclinical proof-of-concept work with partner institutes; planned first-in-human combined Phase 1/2a in sick patients pending remaining preclinical development and capital resources.
Partnerships Max Planck Society / UMG (exclusive option for worldwide license for NanoAbs covered by the RCA)
Indications
Psoriasis(Preclinical)
Psoriatic arthritis(Preclinical)
Status note NanoAbs targeting IL-17A, IL-17F and the IL-17A/F complex selected as drug candidates by the RCA Steering Committee; further development pending preclinical development, capital resources and updated market analysis.
Partnerships Max Planck Society / UMG (exclusive option for worldwide license for NanoAbs covered by the RCA)
Indications
Asthma(Preclinical)
Status note NanoAbs targeting TSLP selected as drug candidates for the potential treatment of asthma by the RCA Steering Committee.
M-001
Phase 3 · TerminatedModality: peptide vaccine
Indications
Universal influenza vaccine(Phase 3)
Status note Prior lead candidate; no longer under development.
Per-asset detail extracted from the 10-Q filed 2023-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.